Settlement with Astellas on Mirabegron patent dispute, USD 90 million payment

Strategic Transactions View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹2208.70

prior close

₹2214.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%-0.6% vs market

Pharmaceuticals peers, median of 159sector+0.4%-0.6% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.0

15m

+0.5

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+0.4-0.6+0.4-0.6

Next day

+0.3+0.4-0.1+0.2+0.0

+0.5-0.1+0.6-0.0+0.5

-0.7-1.7+1.1-1.2+0.5

+0.5-1.3+1.8-1.8+2.3

+1.6-1.0+2.6-1.8+3.4

+0.7-2.1+2.8-2.6+3.3

15d

+4.5-5.7+10.1-7.0+11.5

+6.2-5.4+11.5-5.1+11.3

+5.7-4.4+10.0-3.5+9.2

+1.6+1.1+0.4+3.2-1.7

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin and its US subsidiary have settled a patent infringement dispute with Astellas over the Mirabegron product. Under the agreement, Lupin will pay Astellas USD 90 million (including a USD 75 million prepaid option payment) plus a prepaid per-unit license fee on Mirabegron sales through September 2027. Other settlement terms remain confidential. This resolves the pending litigation, first flagged in April 2025, and allows Lupin to continue selling its Mirabegron product.

Likely market impact

Removes litigation overhang on Mirabegron sales. One-time USD 90 million payout plus ongoing per-unit fees may pressure margins in the near term.